FDA Orange Book · active-ingredient family
Olodaterol hydrochloride; tiotropium bromide
Olodaterol hydrochloride; tiotropium bromide is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
Reference-listed drug:STIOLTO RESPIMAT · NDA 206756
1
Brand (NDA)
0
Generics (ANDA)
7
Listed patents
0
Exclusivity periods
Brand (NDA) products · spray, metered
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| STIOLTO RESPIMATRLD | BOEHRINGER INGELHEIM | NDA 206756 | — | May 21, 2015 |
Listed patents (7)
| Patent | Expires | In | Type |
|---|---|---|---|
| 7396341 | Oct 10, 2026 | in 4 mo | ProductDelisted |
| 7727984 | Jan 19, 2027 | in 7 mo | Substance |
| 9027967 | Mar 31, 2027 | in 10 mo | ProductDelisted |
| 7396341*PED | Apr 10, 2027 | in 10 mo | |
| 7837235 | Mar 13, 2028 | in 1 yr 9 mo | ProductDelisted |
| 7837235*PED | Sep 13, 2028 | in 2 yr 3 mo | |
| 8733341 | Oct 16, 2030 | in 4 yr 5 mo | ProductDelisted |
Olodaterol hydrochloride; tiotropium bromide — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

